Taichung Veterans General Hospital
Part of psoriasis and psoriatic arthritis patients treated with biologics and met primary failure. Therefore, we are going to create a cell based platform to evaluate the treatment effects of different biologics on psoriasis and psoriatic arthritis patients before prescribed by physicians
Dermatologic Disease
Markers data from PBMCs
Not Applicable
PBMCs isolated from psoriasis and psoriatic arthritis and incubated with Group A streptococcus and different biologics for 24 hours. Cytokines expression in the culture supernatants will be measured and the data can be reference for physician's prescription.}}
| Study Type : | Interventional |
| Estimated Enrollment : | 90 participants |
| Masking : | None (Open Label) |
| Primary Purpose : | Screening |
| Official Title : | Personal Precise Treatment on Psoriasis and Psoriatic Arthritis and Investigate the Mechanisms of Biological Agents Induced Systemic Lupus Erythematosus |
| Actual Study Start Date : | May 31, 2021 |
| Estimated Primary Completion Date : | May 31, 2025 |
| Estimated Study Completion Date : | May 31, 2025 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Prescreen on psoriasis and psoriatic arthritis treatment Prescreen markers from individual PBMCs and choose proper biologics before starting treatment on psoriasis and psoriatic arthritis patients. |
Diagnostic Test: Markers data from PBMCs |
| Ages Eligible for Study: | 20 Years to 70 Years |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Accepts Healthy Volunteers |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.